Tagged with P

Egypt PhRMA’s Middle East & Africa (MEA) group appoints a ‘champion’ for each of its markets to bring the priorities of that country to the agenda of the MEA executive committee. Egypt’s champion is Amgen and – as the company’s MEA lead Mohammed Nasser describes – there is much to be…

Canada Drs Neil Cashman and Larry Altstiel of ProMIS Neurosciences weigh in on recent progress towards an effective therapy for Alzheimer’s disease, potentially representing a break from three decades of scientific stagnation.   Are we there yet with Alzheimer’s immunotherapies? No. But we have a map, and it’s a good one.…

UK With the brief tenure of Liz Truss as Prime Minister already drawing to a close, the UK faces yet another new leader as the country attempts to extricate itself from the financial havoc wreaked by the Truss administration. Despite this backdrop, activity continues in the UK’s vibrant healthcare and life…

Europe Victor Mendonça, chair of the Generic Market Access Committee at Medicines for Europe, outlines why patient access to medicines is at risk due to intense price pressure and unprecedented inflation and proposes ways to tackle this. The COVID-19 pandemic and the conflict in Ukraine have caused unprecedented challenges for Europe,…

Pharma Legal Handbook Key legal info on biosimilars & biologics in Denmark. Prepared in association with Gorrissen Federspiel, a leading law firm in Denmark, this is an extract from The Pharma Legal Handbook: Denmark, available to purchase here for GBP 119.   1. Are biosimilar medicines considered the same as generic medicines in…

Vietnam A roundup of recent pharma and healthcare news from Vietnam including Gilead’s viral hepatitis initiative, the country’s explosion of dengue fever cases and the investigation into Boston Scientific’s Vietnam operations.   Gilead initiative to improve viral hepatitis management in Vietnam and the Philippines (BioSpectrum Asia) Gilead Sciences has embarked on…

Pharma Legal Handbook Cannabinoid drugs, medicinal cannabis and opioid drugs in Spain – a legal guide. Prepared in association with Faus Moliner Abogados, a leading law firm in Spain, this is an extract from The Pharma Legal Handbook: Spain, available to purchase here for GBP 119.   Cannabinoid Drugs For the purposes of this Chapter…

Pharma Legal Handbook Want to know more about regulatory reforms in Spain? Read on! Prepared in association with Faus Moliner Abogados, a leading law firm in Spain, this is an extract from The Pharma Legal Handbook: Spain, available to purchase here for GBP 119.   1. Are there proposals for reform or significant change to…

Pharma Legal Handbook The legal framework for patents and trademarks in Spain. Prepared in association with Faus Moliner Abogados, a leading law firm in Spain, this is an extract from The Pharma Legal Handbook: Spain, available to purchase here for GBP 119.   1. What are the basic requirements to obtain patent and trademark protection?…

Pharma Legal Handbook The low-down on the situation regarding product liability in Spain. Prepared in association with Faus Moliner Abogados, a leading law firm in Spain, this is an extract from The Pharma Legal Handbook: Spain, available to purchase here for GBP 119.   1. What types of liability are recognized in your jurisdiction? The…

Pharma Legal Handbook A brief overview of the situation regarding traditional medicines and OTC products in Spain. Prepared in association with Faus Moliner Abogados, a leading law firm in Spain, this is an extract from The Pharma Legal Handbook: Spain, available to purchase here for GBP 119.   1. What are the regulatory requirements for…

Pharma Legal Handbook All about marketing, manufacturing, packaging & labeling, advertising in Spain. Prepared in association with Faus Moliner Abogados, a leading law firm in Spain, this is an extract from The Pharma Legal Handbook: Spain, available to purchase here for GBP 119.   1. What is the authorization process for the marketing…